Xgeva success in Prevention of Bone Metastases in Prostate Cancer

In a phase III study of Zgeva(denosumab), men with castration-resistant prostate cancer and no previous exposure to intravenous bisphosphonate drugs (such as zoledronic acid) were enrolled from 342 centres in 39 countries. Patients were assigned 120 mg subcutaneous denosumab plus intravenous placebo, or 4 mg intravenous zoledronic acid plus subcutaneous placebo, every 4 weeks . Median time to first on-study skeletal-related event was 20.7 months with denosumab compared with 17.1 months with zoledronic acid. Overall, 36% of patients had bone events in the denosumab group compared with 41% in the zoledronic acid group. This study is one of three that have all confirmed the better performance of denosumab compared with zoledronic acid (one published, one in press) in delaying and preventing bone events in men with castration-resistant prostate cancer. see The Lancet, Early Online Publication, 25 February 2011doi:10.1016/S0140-6736(10)62344-6Cite or Link Using DOI "Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study" Prof Karim Fizazi MD et. al.